Cue Biopharma, Inc.

The company is a clinical-stage biopharmaceutical enterprise focused on developing injectable biologic therapies designed to selectively modulate disease-specific T cells. Utilizing its modular Immuno-STAT platform, it seeks to treat autoimmune conditions, inflammatory diseases, and cancers by re-establishing immune balance or clearing pathogenic cells without inducing broad systemic toxicity. Its pipeline includes the CUE-400 series targeting regulatory T cell expansion, the CUE-500 series for targeted pathogenic cell depletion, and the CUE-100 series for oncology applications. As a development-stage entity, the business collaborates with and licenses its candidate molecules to pharmaceutical partners, including Boehringer Ingelheim, ImmunoScape, and LG Chem.

The enterprise maintains an intellectual property estate comprising 161 issued patents and several hundred pending applications across the United States and foreign jurisdictions. Its clinical development, research collaborations, and licensing partnerships extend across the United States, Europe, Australia, and Asia. The provided text contains no mention of the company's headquarters location or specific operating facility counts.

Summary of the business section of Cue Biopharma's latest annual report, written by StockData.

“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.

“As of December 31, 2025, we had 29 full time employees.”